prostate cancer

Data offer new insight on HIFU’s use in low-risk PCaTransrectal HIFU shows a statistically significant increase in per-core negative biopsy rates.
Use of observation for PCa varies widely among urologistsA CMS quality measure needs to be bidirectional, “specifying a rate of observation for low-risk disease and a rate of treatment for high-risk disease,” researchers say.
Peri-op transfusion raises short-term morbidity riskA retrospective analysis looks at the short-term morbidity associated with transfusion among patients in the National Surgical Quality Improvement database.
Study finds prostate Ca clones trackable by fusion biopsySpecific clones may have the potential for grade conversion, research suggests.
AS success rate strong in appropriate PCa patientsLarge study examines surveillance results in men with very low-, low-, intermediate-, and high-risk disease.
Greater long-term side effect risk with intermittent ADTIn men with metastatic prostate cancer, those assigned to intermittent androgen deprivation therapy have more ischemic and thrombotic events than those assigned to continuous androgen deprivation, according to Columbia University researchers.
No link between PDE-5 use, prostate Ca recurrenceNo significant relationship was found between use of a phosphodiesterase type-5 inhibitor and prostate cancer recurrence after treatment in a nested case-control study.
Salvage HIFU shows promise in post-RT PCa patientsHigh-intensity focused ultrasound as salvage therapy allows for intermediate-term disease control in selected patients with recurrence following radiation therapy for prostate cancer.
Modalities for high-risk PCa yield similar outcomesTreatment options for high-risk prostate cancer perform similarly. In a single-institution study, radical prostatectomy was associated with worse biochemical failure, less clinical failure, and superior prostate cancer-specific mortality compared with radiation therapy and brachytherapy, reported Jay P. Ciezki, MD, at the 2016 Genitourinary Cancers Symposium in San Francisco.